Fragment-based drug discovery specialist Graffinity Pharmaceuticals has agreed a drug discovery research collaboration with Genentech.
Under the terms of the agreement, Graffinity will receive technology access fees and optional payments for follow-up chemistry for the generation of novel, small-molecule hits against a number of drug targets. Financial details of the transaction were not disclosed. This is the second agreement between the two companies.
Follow where the public and private R&I money is going and which collaborative opportunities you can pursue.
Receive the Funding Newswire [full access requires a subscription] each Tuesday, our Policy Bulletin each Thursday, and news about bridging Europe’s east-west innovation gap twice a month in The Widening.
Sign up for the Funding Newswire
A unique international forum for public research organisations and companies to connect their external engagement with strategic interests around their R&D system.
